Christopher O'Callaghan, DVM, MSc, PhD

Canadian Cancer Trials Group Senior Investigator

Dr. O'Callaghan received his Doctorate in Veterinary Medicine and MSc and PhD degrees in Epidemiology from the University of Guelph, based on work conducted on the epidemiology of infections of livestock while a Medical Research Council of Canada Fellow at the International Livestock Research Institute in Nairobi, Kenya. He continued his research and training in infectious diseases epidemiology as a Wellcome Trust Senior Research Fellow at the University of Warwick. In 2001 he joined the Canadian Cancer Trials Group where he continues to oversee the Gastrointestinal and Brain Site Committees as Senior Investigator. He is also a Professor in the Department of Public Health Sciences. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology.

Areas of expertise: Gastrointestinal, Brain

Research interests: Clinical trials design, Methodology and Infectious Disease Epidemiology

Current trials: CE7, CE8, CEC6, CO21, CO27, CO28, CRC8, CRC9, GA1, GA3, HE1, BR31

Selected Publications:

  1. Conroy T, Hammel P, Hebbar M,  Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O’Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan and Bachet JB (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. The New England Journal of Medicine 379: 2395-2406
  2. Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross G, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. The New England Journal of Medicine 376: 1027-1037
  3. Crook J, O'Callaghan CJ, Duncan G, Dearnaley D, Higano C, Horwitz E, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg L, Gospodarowicz M, Saad F, Logue J, Hall E, Schellhammer P, Ding K and Klotz L (2012). Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. New England Journal of Medicine 367: 895-903
  4. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine  359: 1757-1765
  5. Jonker DJ*, O’Callaghan CJ*, Karapetis CS, Zalcberg JR, Tu D, Au H-J, Berry SR,  Krahn M, Price T, Simes RJ,  Tebbutt NC, Van Hazel G, Wierzbicki R, Langer C and Moore MJ. (2007) Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine 357: 2040-2048

For a full list of publications please visit PubMed.